AG
ONCE

Artal Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Artal Group’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-50,000
Closed -$2.99M – 126
2017
Q2 		$2.99M Hold
50,000
– – 0.05% 83
2017
Q1 		$2.67M Hold
50,000
– – 0.06% 79
2016
Q4 		$2.5M Hold
50,000
– – 0.06% 73
2016
Q3 		$3M Hold
50,000
– – 0.06% 74
2016
Q2 		$2.56M Buy
+50,000
New +$2.14M 0.05% 56
2015
Q2 		– Sell
-60,000
Closed -$4.65M – 93
2015
Q1 		$4.65M Buy
+60,000
New +$3.46M 0.22% 59

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Artal Group's ONCE Position: Q3 2017 in Review

Artal Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2017, closing a stake of 50,000 shares — an estimated $2.99M sold.

Artal Group first reported a position in ONCE in Q1 2015 and held it in 6 quarters. The position peaked at $4.65M in Q1 2015. 163 funds tracked by Wall St. Rank hold ONCE as of Q3 2017.

  • Artal Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Artal Group sold 50,000 Spark Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $2.99M.
  • Artal Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 6 quarters.
  • Artal Group's Spark Therapeutics, Inc. Common Stock position peaked at $4.65M in Q1 2015.
  • 163 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.